<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8F040A04-142E-43C9-BBAA-33D2D726CC93"><gtr:id>8F040A04-142E-43C9-BBAA-33D2D726CC93</gtr:id><gtr:name>The Statens Serum Institute (SSI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78CA1442-F154-40E7-964B-12FE667ADBE0"><gtr:id>78CA1442-F154-40E7-964B-12FE667ADBE0</gtr:id><gtr:name>Hvidovre Hospital</gtr:name><gtr:address><gtr:line1>Hvidovre Hospital</gtr:line1><gtr:line2>Kettegard Alle 30</gtr:line2><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B96272D9-51DB-4698-AC93-6F9823C379D9"><gtr:id>B96272D9-51DB-4698-AC93-6F9823C379D9</gtr:id><gtr:name>University of Manitoba</gtr:name><gtr:address><gtr:line1>University of Manitoba</gtr:line1><gtr:line4>Winnipeg</gtr:line4><gtr:line5>Manitoba</gtr:line5><gtr:postCode>R3T 2N2</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Infectious Disease Epidemiology</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8F040A04-142E-43C9-BBAA-33D2D726CC93"><gtr:id>8F040A04-142E-43C9-BBAA-33D2D726CC93</gtr:id><gtr:name>The Statens Serum Institute (SSI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78CA1442-F154-40E7-964B-12FE667ADBE0"><gtr:id>78CA1442-F154-40E7-964B-12FE667ADBE0</gtr:id><gtr:name>Hvidovre Hospital</gtr:name><gtr:address><gtr:line1>Hvidovre Hospital</gtr:line1><gtr:line2>Kettegard Alle 30</gtr:line2><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B96272D9-51DB-4698-AC93-6F9823C379D9"><gtr:id>B96272D9-51DB-4698-AC93-6F9823C379D9</gtr:id><gtr:name>University of Manitoba</gtr:name><gtr:address><gtr:line1>University of Manitoba</gtr:line1><gtr:line4>Winnipeg</gtr:line4><gtr:line5>Manitoba</gtr:line5><gtr:postCode>R3T 2N2</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F6567C08-7E8C-4209-BEFD-11307734DE88"><gtr:id>F6567C08-7E8C-4209-BEFD-11307734DE88</gtr:id><gtr:firstName>Bethan</gtr:firstName><gtr:otherNames>Wynne</gtr:otherNames><gtr:surname>Davies</gtr:surname><gtr:orcidId>0000-0002-6585-7641</gtr:orcidId><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902120"><gtr:id>0F59A623-CB18-41F4-B70B-D64190BC6700</gtr:id><gtr:title>The contribution of Chlamydia trachomatis to adverse reproductive health and the implications for control policy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902120</gtr:grantReference><gtr:abstractText>Chlamydia is one of the commonest sexually transmitted bacterial infections in Europe. Most people have no symptoms, but left untreated it can cause serious complications, including infertility. Screening programmes can identify and treat asymptomatic people and reduce long-term complications. However these programmes have costs, personal and financial, that must be balanced against their benefit. 

In order to do this we need to know how often complications occur after an infection. But the evidence on this is limited and based mainly on old studies that may not be relevant today. 

The proposed research will review current knowledge about the association between chlamydia and reproductive health and then measure this association using information collected from residents of Manitoba Province, Canada, over the last 25 years. These findings will be used to develop a 



mathematical model to estimate the potential impact of Chlamydia screening and to determine whether screening programmes are cost effective. Finally, interviews will be conducted with key professionals and public and patient representatives to understand the factors that influence screening policy. The research will conclude by drawing together the findings from each study to produce evidence based policy recommendations for Chlamydia screening.</gtr:abstractText><gtr:technicalSummary>Chlamydia trachomatis (CT) is one of the commonest sexually transmitted bacterial infections in Europe. Untreated infection can lead to serious adverse reproductive outcomes but these can be prevented by diagnosing and treating infections. The control of CT is a public health priority and there is evidence to show that screening can reduce the incidence of complications. Investment in control programmes is mainly justified in order to reduce long term complications, including pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility. However, at present there are no consensus estimates of the risk of these complications following an infection. 

The aim of this research is to improve knowledge about the natural history of CT infection and use this to estimate the population attributable risk of CT for adverse reproductive health in order to improve estimates of the cost effectiveness of CT control activities. 

The gaps in the current evidence base around the natural history of CT and the cost effectiveness of control strategies will be addressed using a range of research methods. Firstly, a systematic review of the literature will be completed to update current estimates of the association between CT and adverse reproductive outcomes. Secondly, quantitative analysis of a large historical population cohort will be performed to measure the association between a diagnosis of CT and the chronic consequences. This work will then be used to inform the assumptions in a mathematical model of the transmission dynamics of CT that will be developed and used to inform cost effectiveness analysis of CT control strategies. Finally, qualitative techniques will be used to develop an understanding of the CT control policy context. The findings of the proposed research will be used to formulate policy recommendations.

The proposed research will provide a comprehensive multidisciplinary training in research and it will advance current knowledge on the natural history of CT and the cost effectiveness of control strategies to inform policy at a regional, national and international level.</gtr:technicalSummary><gtr:fund><gtr:end>2014-10-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-07-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>188649</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manitoba</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Centre for Global Public Health</gtr:department><gtr:description>University of Manitoba</gtr:description><gtr:id>4D21970A-9370-4F24-80CF-545F85F4482B</gtr:id><gtr:impact>Davies B; Ward H; Leung S; Turner K; Garnett G; Blanchard J; Yu N. (Nov 2014) Heterogeneity in risk of pelvic inflammatory disease following chlamydia infection: a population based study in Manitoba, Canada. Journal of Infectious Diseases, 210, S549-S555. http://dx.doi.org/10.1093/infdis/jiu483</gtr:impact><gtr:outcomeId>BxQqsA4UaH1-1</gtr:outcomeId><gtr:partnerContribution>Access to data for research project, data analysis, intellectual input and technical expertise</gtr:partnerContribution><gtr:piContribution>Research design/ intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Experimental Psychology</gtr:department><gtr:description>Dr Katy Turner, University of Bristol</gtr:description><gtr:id>8B70B141-C68A-4D23-8514-2C58E3693EF9</gtr:id><gtr:impact>Peer-reviewed publication; conference presentations</gtr:impact><gtr:outcomeId>5899b391be28b1.32258773-1</gtr:outcomeId><gtr:partnerContribution>Collaboration for the analysis of the Denmark Chlamydia Cohort</gtr:partnerContribution><gtr:piContribution>Collaboration for the analysis of the Denmark Chlamydia Cohort</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hvidovre Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>State Serum Institute, Denmark</gtr:description><gtr:id>1BD51A1E-D11B-435D-B701-285EFDA44AFB</gtr:id><gtr:impact>PhD thesis; publications/presentations; further work in progress</gtr:impact><gtr:outcomeId>CH7PEnSeJ4u-2</gtr:outcomeId><gtr:partnerContribution>Data for analysis; intellectual input to study design</gtr:partnerContribution><gtr:piContribution>Data analysis; intellectual input to study design</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Statens Serum Institute (SSI)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>State Serum Institute, Denmark</gtr:description><gtr:id>7482F1C0-F34C-44D9-81E2-DA8BB3046B24</gtr:id><gtr:impact>PhD thesis; publications/presentations; further work in progress</gtr:impact><gtr:outcomeId>CH7PEnSeJ4u-1</gtr:outcomeId><gtr:partnerContribution>Data for analysis; intellectual input to study design</gtr:partnerContribution><gtr:piContribution>Data analysis; intellectual input to study design</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in ECDC Qualitative evaluation of 2009 chlamydia control guidance</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>07E64139-3960-46A4-A87F-2B7C4039D97B</gtr:id><gtr:outcomeId>56bdb9ad50ac10.07034955</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://ecdc.europa.eu/en/publications/Publications/chlamydia-control-europe-guidance-evaluation-march-2015.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7CE0AC19-FDAE-4C7E-A0AE-B4F6A757AB4E</gtr:id><gtr:title>Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39805b81c63c9d4885e43efb917b3d25"><gtr:id>39805b81c63c9d4885e43efb917b3d25</gtr:id><gtr:otherNames>Davies B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>589af4d6b23799.92734299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43CC7E3C-FE73-43D3-9548-9793CC5B5164</gtr:id><gtr:title>How robust are the natural history parameters used in chlamydia transmission dynamic models? A systematic review.</gtr:title><gtr:parentPublicationTitle>Theoretical biology &amp; medical modelling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39805b81c63c9d4885e43efb917b3d25"><gtr:id>39805b81c63c9d4885e43efb917b3d25</gtr:id><gtr:otherNames>Davies B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-4682</gtr:issn><gtr:outcomeId>54539ae3ce8293.26016540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01AECB9B-7BC0-4F94-9FFF-3028C39BC541</gtr:id><gtr:title>Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39805b81c63c9d4885e43efb917b3d25"><gtr:id>39805b81c63c9d4885e43efb917b3d25</gtr:id><gtr:otherNames>Davies B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a2fd6c2db8172.37945354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E587806-4C03-47CB-848A-7ADDAD75CB36</gtr:id><gtr:title>Risk of pelvic inflammatory disease after Chlamydia infection in a prospective cohort of sex workers.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39805b81c63c9d4885e43efb917b3d25"><gtr:id>39805b81c63c9d4885e43efb917b3d25</gtr:id><gtr:otherNames>Davies B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn><gtr:outcomeId>doi_17338_31827b9d75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>395F0BC8-54EA-4216-9514-569A7039ABD5</gtr:id><gtr:title>Heterogeneity in risk of pelvic inflammatory diseases after chlamydia infection: a population-based study in Manitoba, Canada.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39805b81c63c9d4885e43efb917b3d25"><gtr:id>39805b81c63c9d4885e43efb917b3d25</gtr:id><gtr:otherNames>Davies B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5463cbea503512.18683365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0FF8407-58C5-4DE0-B318-8526621242EC</gtr:id><gtr:title>Genital chlamydia prevalence in Europe and non-European high income countries: systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b7dbbbaf5e1c40e86a44aaab0422a9d"><gtr:id>3b7dbbbaf5e1c40e86a44aaab0422a9d</gtr:id><gtr:otherNames>Redmond SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a578c264f0209.83201443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BB1C439-AD03-46E4-AEA9-36B2A2FE88D6</gtr:id><gtr:title>A pathway to chlamydia control: updated ECDC guidance.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39805b81c63c9d4885e43efb917b3d25"><gtr:id>39805b81c63c9d4885e43efb917b3d25</gtr:id><gtr:otherNames>Davies B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>585d3b6ce54895.62999589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3538E87C-BA35-4EE5-974E-1C96B678106C</gtr:id><gtr:title>Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39805b81c63c9d4885e43efb917b3d25"><gtr:id>39805b81c63c9d4885e43efb917b3d25</gtr:id><gtr:otherNames>Davies B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5899b1df207917.54847556</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902120</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>5C2ACE0A-A29E-4DCC-9F5A-B00BFAB172B9</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.4  Population screening</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>